News

What goes wrong first in the Alzheimer’s disease brain? Scientists led by Marc Aurel Busche of the U.K. Dementia Research Institute at University College London may have an answer. In the May 7 Neuron ...
Atherosclerotic arteries aren’t just a problem for the heart—they’re bad news for the brain, too. Now, scientists led by Wei Wang, Dai-Shi Tian, and Chuan Qin of Huazhong University of Science and ...
Neurofibrillary tangles mark Alzheimer’s disease and a plethora of primary tauopathies. How best to study them in the lab? Most mouse tauopathy models overexpress the human tau protein and are highly ...
In a milestone for Alzheimer’s disease diagnosis and care, the U.S. Food and Drug Administration on May 16 cleared for marketing the first AD blood test. Fujirebio’s Lumipulse G p-tau217/Aβ42 ...
As biomarker testing becomes more common in Alzheimer’s research, scientists face the tricky question of whether to disclose results. In studies of hypothetical scenarios, including a recent survey ...
Delivery Courier? Microglia Drop Neprilysin Off Near Plaques in Brain Add To My AlzForum 5 Comments 25 Apr 2025 The cells reduced the amount of amyloid and improved downstream aspects of Alzheimer’s ...
As advanced biomedical technologies have allowed scientists to gather growing and increasingly complex datasets, even the most brilliant human minds grappling with the windfall can’t possibly keep up.
As the baby boom generation reaches its hopefully golden years, scientists have been projecting a doubling of dementia cases in the U.S. by 2050, alarming health care agencies, the public, and health ...
Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of ...
With two anti-amyloid antibodies now in clinical use, improving the safety of these treatments is front and center on clinicians’ minds. In the year since lecanemab was approved by the Food and Drug ...
For 30 years, APOE4 has ranked as the strongest genetic risk factor for Alzheimer’s disease, with two copies boosting the odds up to 15-fold. Now, scientists argue that people with two APOE4 alleles ...